Hemato-Oncology Hemato-Oncology October 26, 2025 Posted by myadmin 28 Dec A Randomized, Open-Label, Multicenter, Phase 3 Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP Versus R-CHOP in Par...Continue reading
